JNJ Options Trading Surges as Investors Bet on Further Gains

Unusually large options trading in Johnson & Johnson (NYSE:JNJ) stock on Tuesday caught attention. The company saw an increase of approximately 29% in call option volume, with traders buying 34,603 contracts. This surge in activity indicates increased speculative interest in further gains.

The recent performance of J&J has been strong, with the company reporting second-quarter sales of $25.31 billion, a 6.6% year-over-year increase. Adjusted earnings per share (EPS) of $2.90 exceeded analysts' expectations, and management raised its 2026 outlook, reinforcing confidence in near-term earnings growth.

Additionally, the FDA cleared the AI-powered MONARCH QUEST 3 bronchoscopy system, which adds robotic visualization, airway-access capabilities, and AI-assisted planning and imaging support to J&J's portfolio. This move has investors increasingly viewing immunology and neuroscience as growth engines for the company.